Key facts
- It has raised $1.3M across 1 recorded rounds; the latest was Angel (individual) in Jan 2025.
- Notable investors include Keiretsu Forum, CONNECT (San Diego), Band of Angels, Jumpstart Ventures, Angel Physicians Fund — 8 tracked in total.
- MuReva Phototherapy has filed 1 Form D with the SEC, most recently Dec 2018 ($1.3M sold to 18 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for MuReva Phototherapy
Funding rounds
1 roundsAbout MuReva Phototherapy
Developer of medical therapeutic devices designed to treat oral mucositis. The company's technology utilizes photobiomodulation by emitting lasers to treat the damage caused by cancer-killing therapies, helping reduce mucosal injury in patients undergoing radiation and chemotherapy for various cancers and also eliminate mouth ulcers, the most common, debilitating and costly side effect of cancer therapy, enabling patients to have a technology that can treat and potentially prevent this terrible side effect
- Sector
- Healthcare
- HQ
- Brecksville, OH, United States
- Founded
- 2018
- Employees
- 10
- Website
- murevapt.com/
- Ownership
- Privately Held (backing)
MuReva Phototherapy doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MuReva Phototherapy shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MuReva Phototherapy in its N-PORT filings yet. We sweep new filings monthly.